Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Presymptomatic Parkinson's disease: the Arizona experience.

Caviness JN.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S203-6. doi: 10.1016/S1353-8020(11)70063-3. Review.

PMID:
22166435
2.

Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease.

Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE.

Acta Neuropathol. 2008 Apr;115(4):437-44. doi: 10.1007/s00401-008-0345-7. Epub 2008 Feb 9.

PMID:
18264713
3.

Differential spectral quantitative electroencephalography patterns between control and Parkinson's disease cohorts.

Caviness JN, Utianski RL, Hentz JG, Beach TG, Dugger BN, Shill HA, Driver-Dunckley ED, Sabbagh MN, Mehta S, Adler CH.

Eur J Neurol. 2016 Feb;23(2):387-92. doi: 10.1111/ene.12878. Epub 2015 Oct 31.

PMID:
26518336
4.

Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders.

Caviness JN, Adler CH, Hentz JG, Shill HA, Evidente VG, Driver-Dunckley ED, Sabbagh MN, Sue L, Beach TG.

Clin Neurophysiol. 2011 Dec;122(12):2426-32. doi: 10.1016/j.clinph.2011.03.033. Epub 2011 May 26.

5.

Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.

Jellinger KA.

Acta Neuropathol. 2003 Sep;106(3):191-201. Epub 2003 Jul 5. Erratum in: Acta Neuropathol (Berl). 2003 Dec;106(6):588.

PMID:
12845452
6.

Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease.

Frigerio R, Fujishiro H, Maraganore DM, Klos KJ, DelleDonne A, Heckman MG, Crook JE, Josephs KA, Parisi JE, Boeve BF, Dickson DW, Ahlskog JE.

Arch Neurol. 2009 Sep;66(9):1114-9. doi: 10.1001/archneurol.2009.170.

7.

Clinical criteria for the diagnosis of Parkinson's disease.

Reichmann H.

Neurodegener Dis. 2010;7(5):284-90. doi: 10.1159/000314478. Epub 2010 Jul 9. Review.

PMID:
20616563
8.

The evolution of diagnosis in early Parkinson disease. Parkinson Study Group.

Jankovic J, Rajput AH, McDermott MP, Perl DP.

Arch Neurol. 2000 Mar;57(3):369-72.

PMID:
10714663
9.
10.

Incidental Lewy body disease: clinical comparison to a control cohort.

Adler CH, Connor DJ, Hentz JG, Sabbagh MN, Caviness JN, Shill HA, Noble B, Beach TG.

Mov Disord. 2010 Apr 15;25(5):642-6. doi: 10.1002/mds.22971.

11.

Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: studies on Parkinson's and incidental Lewy body disease.

Marshall KA, Daniel SE, Cairns N, Jenner P, Halliwell B.

Biochem Biophys Res Commun. 1997 Nov 7;240(1):84-7.

PMID:
9367887
12.

Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease.

Louis ED, Goldman JE, Powers JM, Fahn S.

Mov Disord. 1995 Mar;10(2):188-94. Review.

PMID:
7753061
14.
15.

Evaluation of a screening questionnaire for genetic studies of Parkinson's disease.

Racette BA, Rundle M, Parsian A, Perlmutter JS.

Am J Med Genet. 1999 Oct 15;88(5):539-43.

PMID:
10490713
16.

Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study.

Ghebremedhin E, Del Tredici K, Langston JW, Braak H.

Acta Neuropathol. 2009 Dec;118(6):777-84. doi: 10.1007/s00401-009-0596-y. Epub 2009 Oct 3.

PMID:
19802627
17.

Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.

During MJ, Kaplitt MG, Stern MB, Eidelberg D.

Hum Gene Ther. 2001 Aug 10;12(12):1589-91.

PMID:
11529246
18.

Increased risk of leg motor restlessness but not RLS in early Parkinson disease.

Gjerstad MD, Tysnes OB, Larsen JP.

Neurology. 2011 Nov 29;77(22):1941-6. doi: 10.1212/WNL.0b013e31823a0cc8. Epub 2011 Nov 9.

PMID:
22076542
19.

Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias.

Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, Burn D, Ballard CG.

J Clin Psychiatry. 2005 May;66(5):633-7.

PMID:
15889951
20.

A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.

Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I; Parkinson Study Group LABS-PD Investigators.

Mov Disord. 2009 Oct 30;24(14):2081-90. doi: 10.1002/mds.22690.

PMID:
19691116

Supplemental Content

Support Center